PeptiDream Inc

PeptiDream Inc maintains a strong liquidity position, with cash and equivalents amounting to ¥28.68 billion, which significantly exceeds its total liabilities of ¥25.50 billion. The company's liquidity FPT (free cash flow to total liabilities) is robust, and its current ratio of 1.66 indicates a solid ability to meet short-term obligations. Despite its strong liquidity, PeptiDream Inc is currently unprofitable, with a net loss of ¥3.75 billion and an operating loss of ¥5.01 billion. Its return on equity (ROE) is -7.28%, and its return on assets (ROA) is -4.87%, both of which are below the industry median for biotechnology firms. The company's negative operating cash flow of ¥13.28 billion and free cash flow of -¥3.38 billion further highlight its ongoing financial challenges. PeptiDream Inc's revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company's revenue of ¥18.52 billion is derived primarily from its drug discovery and development services, with no material revenue from product sales. This concentration increases the company's exposure to market and regulatory risks in the biotechnology sector. The company's growth trajectory is uncertain, with no disclosed revenue growth in the current fiscal year. Analysts have provided a mean price target of ¥2,875.00 and a median price target of ¥2,725.00, with a mean recommendation of 2.00 (indicating a "buy" rating). However, the company's negative operating and net income suggest that it may not achieve significant revenue growth in the near term. PeptiDream Inc faces several risk factors, including its reliance on external financing to fund operations and its lack of commercialized products. The company's debt-to-equity ratio of 0.33 is relatively low, but its negative cash flows and operating losses increase the risk of future dilution. No immediate filing-based liquidity or dilution flags were detected, but the company's capital expenditures of -¥1.75 billion indicate ongoing investment in its research and development activities. Recent events include the company's continued focus on expanding its phage display technology platform and forming partnerships with pharmaceutical companies. The company has also been actively engaged in research and development, with no recent filings indicating significant changes in its business strategy or financial position.